||Last Updated: Nov 17th, 2006 - 22:35:04
Two-component lantibiotic with therapeutic potential discovered
The discovery and preparation of a naturally occurring antibiotic could open the door to new therapeutic drugs for treating nasty infections. The rapid spread of drug-resistant bacterial strains poses a persistent threat to human health, and requires new sources of antibiotics to treat infections. Researchers at the University of Illinois at Urbana-Champaign are tackling this problem by discovering and preparing natural antibiotics called lantibiotics.
Oct 31, 2006, 16:13
Antibiotic inhibits cancer gene activity
A little-known antibiotic shows early promise as an anti-cancer agent, inhibiting a gene found at higher-than-normal levels in most human tumors, according to researchers at the University of Illinois at Chicago College of Medicine.
Oct 2, 2006, 01:39
Rapamycin shown to inhibit angiogenesis
Scientists have long known that the blood vessels of tumors differ markedly from normal blood vessels. Now, a research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC) has identified a signaling pathway which, when activated, transforms otherwise healthy blood vessels into the leaky, misshapen vasculature that characterizes cancerous tumors.
Aug 15, 2006, 02:48
Tigecycline, world’s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Tygacil (tigecycline), a new, expanded broad-spectrum IV antibiotic for the treatment of a wide range of infections including those caused by antibiotic resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), 1 will be available in the UK from 20 June 2006. Availability of this new antibiotic comes at a time when the need for effective new treatments is greater than ever and clinicians are running out of options.
Jul 22, 2006, 19:18
FDA Warns of Liver Failure With Telithromycin
The Food and Drug Administration (FDA) today completed its safety assessment of Telithromycin and is advising health practitioners and patients to be aware of rare but potentially serious health risks. Ketek (telithromycin) is the first FDA-approved antibiotic of the ketolide class. It is indicated for the treatment of acute exacerbation of chronic bronchitis; acute bacterial sinusitis; and community acquired pneumonia of mild to moderate severity, including pneumonia caused by resistant strep infections. The drug has been associated with rare cases of serious liver injury and liver failure with four reported deaths and one liver transplant after the administration of the drug. The manufacturer is revising the drug labeling to address this safety concern.
Jun 30, 2006, 13:13
What is the optimal duration of antibiotic therapy?
Taking antibiotics for three days is just as effective for community acquired pneumonia as continuing treatment for the recommended 7-10 days, finds a study in this week’s BMJ. Shorter treatment can also help contain growing resistance rates. The study raises questions about the optimal duration of antibiotic therapy for common infections. Community acquired pneumonia is one of the most important indications for antibiotic prescriptions in hospitals. But a lack of evidence to support short course therapy means it has become accepted practice to continue treatment for days after symptoms have improved.
Jun 10, 2006, 17:48
Should children with suspected meningitis be given antibiotics before transfer to hospital?
Several European countries advise doctors in primary care to do this, but the evidence is conflicting, with some studies suggesting benefit and others suggesting harm. Two papers in this week’s BMJ add to this uncertainty.
Jun 2, 2006, 23:05
Production Practices Effect Antimicrobial Resistance in Poultry
The use of conventional versus organic production practices can significantly affect the prevalence of antibiotic resistant to bacteria in poultry say researchers from Maryland and Ohio. Their findings appear in the May 2006 issue of the journal Applied and Environmental Microbiology.
May 15, 2006, 17:27
Aspirin Protects Against Aminoglycoside Induced Hearing Loss
Around the world, inexpensive antibiotics known as aminoglycosides have been used for the past 60 years in the battles against acute infections and tuberculosis as antibacterial prophylaxis in cystic fibrosis patients and in other conditions. But for all of the good they do, the drugs also have been widely linked to irreversible hearing loss. Now, researchers at the University of Michigan's Kresge Hearing Research Institute and their Chinese colleagues, working under the leadership of Jochen Schacht, Ph.D., and Su-Hua Sha, M.D., have found that the hearing loss can be prevented in many people with the use of another inexpensive, widely available medication: aspirin. The results appear in the April 27 issue of the New England Journal of Medicine.
Apr 27, 2006, 13:45
Avelox (Moxifloxacin) is as effective as Levofloxacin combination therapy for severe community-acquired pneumonia
AVELOX (moxifloxacin HCl) monotherapy at 400 mg once daily is as effective as the high-dose combination of levofloxacin (500 mg twice daily) plus ceftriaxone (2 g once daily) in treating patients with severe community-acquired pneumonia (CAP) requiring hospitalization, according to results of a new clinical study presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Nice, France.
Apr 9, 2006, 12:44
Rapamycin (sirolimus) also effective in ADPKD
A widely available drug may be effective in treating kidney disease, report scientists at the University of California, Santa Barbara. They describe the discovery in the online edition of the Proceedings of the National Academies of Science published the week of March 20.
Mar 22, 2006, 08:26
Study of antibiotic resistance in the soil help predict future clinical emergence
Dirt may be a key to how bacteria that infect humans develop a resistance to antibiotic drugs. In an article in the January 20 issue of the journal Science, McMaster University researchers say that study of bacteria found in dirt may be the key in identifying how and why antibiotic resistance happens in bacteria that infect people, predicting future clinical problems, and testing new antibiotics. Antibiotic resistance has become an increasing public health concern because the organisms that cause infections in humans and animals are becoming less receptive to the healing aspect of antibiotic drugs.
Jan 20, 2006, 15:40
New peptide antibiotic - American Oyster Defensin (AOD)
North Carolina Sea Grant researchers have isolated a new peptide antibiotic from the American oyster that may have implications for managing many diseases in oysters. The new antimicrobial peptide "American oyster defensin" (AOD) may protect against bacteria in Crassostrea virginica, a species that is native to North Carolina and important economically to Atlantic and Gulf Coast fisheries.
Dec 1, 2005, 05:46
Reducing Antibiotic Use Lowers Rates of Drug-Resistant Bacteria
Fewer antibiotic prescriptions leads to fewer “superbugs.” That’s the take-home message behind a new study in the Oct. 15 issue of Clinical Infectious Diseases, now available online. The study found that reducing antibiotic use for pediatric respiratory tract infections resulted in lower rates of carriage of drug-resistant bacteria.
Sep 4, 2005, 08:03
Research to Study Effects of Antibiotics on Intestinal Microbes
The tiny organisms that live inside of us play a huge role in our health, yet we don’t know much about them. In sheer numbers, the bacteria in our body outnumber our own cells tenfold. They perform tasks that are beneficial (processing nutrients, helping store fat and providing protection against invading pathogens) and harmful (being a potential source of infection, creating carcinogens and triggering chronic illnesses).
Apr 10, 2005, 09:25
NADH Dehydrogenase Inhibitors suggested to be new Anti-Tubercular Antibiotics
A worldwide health problem, tuberculosis kills more people than any other bacterial infection. The World Health Organization estimates that two billion people are infected with TB, and that two million people die each year from the disease. However, due to multi-drug resistance and a protracted medication regimen, it is extremely difficult to treat. Hence, there is still a great deal of interest in developing new anti-tubercular drugs. Researchers at the University of Pennsylvania School of Medicine have identified a biochemical target that could lead to a new class of antibiotics to fight TB. They report their findings in this week's online edition of the Proceedings of the National Academy of Sciences.
Mar 11, 2005, 17:22
A Microdialysis Technique will Help to Design and Test New Antibiotics
Now UF researchers have devised a patent-pending method that combines testing of various drug concentrations at the site of infection with a series of laboratory analyses and mathematical models designed to streamline drug development. The method helps better determine which drugs are worth studying in people and at which dose, avoiding the typically lengthy and expensive trial-and-error approach that can take years.
Mar 5, 2005, 07:00
Peptide Deformylase Inhibitors : A Novel Class of Antibiotics for Resistant Bacteria
Peptide deformylase inhibitors constitute one of the most promising new antibiotic classes and hold the potential to treat large markets of community bacterial infections. The peptide deformylase inhibitor class of antibiotics targets a novel protein that is essential for bacterial growth and provides the basis for selective activity toward a wide range of bacterial pathogens. This new class has already demonstrated promising in vitro and in vivo activities against a broad spectrum of bacteria, including those resistant to widely used penicillin, cephalosporin, macrolide, and quinolone antibiotics.
Mar 5, 2005, 06:50